Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation

Cancer Discovery

Volumn 6, Issue 4, 2016, Pages 368-381

  Elf, Shannon ^a   Abdelfattah, Nouran S ^a   Chen, Edwin ^a   Perales Patón, Javier ^b   Rosen, Emily A ^a   Ko, Amy ^a   Peisker, Fabian ^a   Florescu, Natalie ^a   Giannini, Silvia ^a   Wolach, Ofir ^a   Morgan, Elizabeth A ^a   Tothova, Zuzana ^a,c,d   Losman, Julie Aurore ^c,d   Schneider, Rebekka K ^a   Al Shahrour, Fatima ^b   Mullally, Ann ^a,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Structural Biology and Biocomputing Programme   (Spain)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CASPASE 9; CYTOKINE RECEPTOR; JANUS KINASE 1; PHOSPHOPROTEIN; STAT PROTEIN; THROMBOPOIETIN RECEPTOR; JANUS KINASE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALR GENE; CELL GROWTH ASSAY; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; ONCOGENESIS AND MALIGNANT TRANSFORMATION; POLYMERASE CHAIN REACTION; PROTEIN BINDING; SHORT TANDEM REPEAT; SOMATIC MUTATION; STATIC ELECTRICITY; STREPTOCOCCUS PYOGENES; TUMOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW TRANSPLANTATION; CELL LINE; CELL TRANSFORMATION; CHEMISTRY; DISEASE MODEL; FRAMESHIFT MUTATION; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MUTATION; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; STRUCTURE COLLAPSE;

ANIMALS; BASE SEQUENCE; BONE MARROW TRANSPLANTATION; CALRETICULIN; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; FRAMESHIFT MUTATION; HEMATOPOIETIC STEM CELLS; HUMANS; JANUS KINASES; MICE; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STRUCTURE COLLAPSE;

EID: 84962360217     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-1434     Document Type: Article

References (45)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452-66.
2. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112: 2190-8.
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.
4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-8.
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90.
6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly B J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97.
7. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS medicine 2006; 3: e270.
8. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-6.
9. Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988-92.
10. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182-92.
11. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamazaki S, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904-8.
12. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 118: 1723-35.
13. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-90.
14. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-405.
15. Tannous A, Pisoni GB, Hebert DN, Molinari M. N-linked sugarregulated protein folding and quality control in the ER. Semin Cell Dev Biol 2015; 41: 79-89.
16. Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M. Calreticulin: one protein, one gene, many functions. Biochem J 1999; 344 Pt 2: 281-92.
17. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-30.
18. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 1990; 87: 6649-53.
19. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res 2006; 66: 11156-65.
20. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-60.
21. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006; 107: 4274-81.
22. Zaleskas VM, Krause DS, Lazarides K, Patel N, Hu Y, Li S, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One 2006; 1: e18.
23. Mullally A, Lane SW, Brumme K, Ebert BL. Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am 2012; 26: 1065-81.
24. Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia 2014; 28: 1811-8.
25. Stein H, Bob R, Durkop H, Erck C, Kampfe D, Kvasnicka HM, et al. A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies. Leukemia 2016; 30: 131-5.
26. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 1988; 85: 9312-6.
27. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005; 102: 18962-7.
28. Komatsu N, Nakauchi H, Miwa A, Ishihara T, Eguchi M, Moroi M, et al. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res 1991; 51: 341-8.
29. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 2014; 32: 1262-7.
30. Basham B, Sathe M, Grein J, McClanahan T, D'Andrea A, Lees E, et al. In vivo identification of novel STAT5 target genes. Nucleic Acids Res 2008; 36: 3802-18.
31. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene 2007; 26: 6724-37.
32. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, et al. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol 2007; 27: 4444-53.
33. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-27.
34. Moremen KW, Molinari M. N-linked glycan recognition and processing: the molecular basis of endoplasmic reticulum quality control. Curr Opin Struct Biol 2006; 16: 592-9.
35. Marty C, Pecquet C, Nivarthi H, Elkhoury M, Chachoua I, Tulliez M, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood 2016; 127: 1317-24.
36. C hachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu RI, Marty C, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 2016; 127: 1325-35.
37. Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 2016; 127: 1307-16.
38. Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008; 111: 3751-9.
39. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014; 123: 1544-51.
40. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 2014; 124: 1062-9.
41. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014; 123: e123-33.
42. Passamonti F, Caramazza D, Maffioli M. JAK inhibitor in CALRmutant myelofibrosis. N Engl J Med 2014; 370: 1168-9.
43. Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Hematology Am Soc Hematol Educ Program 2014; 2014: 268-76.
44. Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell 2015; 160: 1196-208.
45. Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 2016; 30: 431-8.